Psound Bytes™

National Psoriasis Foundation presents Psound Bytes™, a podcast series about living with psoriasis and psoriatic arthritis with leading experts discussing topics that offer a better understanding of the disease and management, to coping and thriving with the disease. Listen to world renowned dermatologists and rheumatologists discuss the latest news in psoriatic disease management.

Ep. 254 "If You Have Psoriatic Disease Keep an Eye Out for Uveitis" 06/03/2025

Ep. 254 "If You Have Psoriatic Disease Keep an Eye Out for Uveitis" Have a red, painful eye that’s sensitive to light? Could be uveitis. Hear ophthalmologist Dr. Timothy Janetos discuss uveitis and how it relates to psoriasis and psoriatic arthritis. Join host Takieyah Mathis for an eye opening discussion about uveitis, cataracts, and eye health with ophthalmologist Dr. Timonthy Janetos from Northwestern Medicine, Department of Ophthalmology. Listen as they discuss what is uveitis and cataracts from key symptoms, the significance of the HLA-B27 marker, diagnosis, to treatment options that help reduce inflammation and preserve long term vision. This episode offers information to help you advocate for your eye health by recognizing when you need help from an ophthalmologist and what actions you can take to reduce your risks associated with uveitis. Timestamps: · (0:00) Intro to Psound Bytes & guest welcome ophthalmologist Dr. Timothy Milton Janetos. · (1:21) Definition of uveitis and the relationship to psoriatic disease. · (5:35) Symptoms of uveitis. · (7:45) How uveitis is diagnosed. · (9:24) Treatment options for uveitis. · (13:11) What happens if eye injections are needed as treatment. · (14:47) Association between inflammation, psoriatic disease, and cataracts. · (15:48) Symptoms of a cataract. · (16:33) Treatment for cataracts. · (21:11) New advancements in treating uveitis and cataracts. · (25:50) General eye health actions to help reduce risks associated with inflammation. Early detection is key. 4 Key Takeaways: · Uveitis is a huge spectrum of different diseases with about half of the associations due to chronic, immune related diseases like psoriasis or psoriatic arthritis. · If you wake up with a red, painful eye that’s sensitive to light, seek help from an ophthalmologist right away to minimize risk of scar tissue formation. · Work with a health care team to treat all aspects of psoriatic disease to reduce inflammation whether it’s in the skin, joints, and/or the eye. · Lifestyle changes such as stop smoking and yearly eye exams are actions that can help reduce inflammatory factors and maintain overall eye health. Guest Bio: Dr. Timothy Milton Janetos is a board-certified and nationally recognized ophthalmologist with Northwestern Medicine, Department of Ophthalmology who specializes in uveitis and cataract surgery. He is also an Assistant Professor at the Feinberg School of Medicine, Department of Ophthalmology. Dr. Janetos offers comprehensive care using a personalized treatment plan for both children and adults with intraocular inflammation and infections. He is a professional member of the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO), as well as the Editor for Frontiers in Ophthalmology and an Editorial Board Member for Annals of Eye Science. Resources: Ø Psoriatic Arthritis and Uveitis: What’s it All About? Podcast with rheumatologist and ophthalmologist Dr. James Rosenbaum. (Released in 2019.) Ø Eye Inflammation and Psoriatic Arthritis /episode/index/show/psoundbytes/id/36829655

Ep. 253 "Inflammation is Bad for Bone: Osteoporosis and Psoriatic Disease" 05/29/2025

Ep. 253 "Inflammation is Bad for Bone: Osteoporosis and Psoriatic Disease" Osteoporosis is a silent disease. There is no pain or other symptoms but inflammation in the gut and joints is a risk factor. Learn about your risks and what you can do for osteoporosis from rheumatologist Dr. Diana Sandler. Join host Corinne Rutkowski, a third year medical student, as she explores the relationship between osteoporosis and psoriasis with leading bone health expert and rheumatologist Dr. Diana Sandler. Listen as they discuss the difference between osteoporosis and osteoarthritis, bone density testing, how prolonged inflammation is a key risk factor especially for psoriatic arthritis, along with treatments and actions you can take to minimize your risk of osteoporosis and fractures. Do what you can to protect your bone health and function as you age. Timestamps: (00:00) Intro to Psound Bytes & guest welcome rheumatologist Dr. Diana Sandler. (01:23) Risk factors and difference between osteoporosis and osteopenia. (03:10) Difference between osteoporosis and osteoarthritis, which are often confused. (04:17) Diagnosis process for osteoporosis. (06:11) Risk factors for development of osteoporosis. (07:57) Is it possible to have osteoporosis or osteopenia and psoriatic arthritis together? (09:44) The role of osteoclast and osteoblasts in bone formation. (12:21) Treatment of osteoporosis. (14:10) Importance of vitamin D and calcium in the prevention of osteoporosis. (15:57) Activities that strengthen the muscles and bones to slow progression of osteoporosis. (17:08) Precautions and tips for avoiding falls. (18:59) Schedule appointments and ask for referrals early. 4 Key Takeaways: · Osteoporosis and osteoarthritis are two distinct diseases that affect joints and bone. · There are many factors that impact the development of osteoporosis including inflammatory diseases such as psoriatic arthritis, lifestyle risks, family history, use of steroids, hormone deprivation, and more. · Preventive use of bisphosphonates and other treatment strategies can be implemented to address the breakdown of bone in osteoporosis. · Various precautions can be taken to minimize and avoid falls. Guest Bio: Dr. Diana Sandler is a rheumatologist at Endeavor Health in Chicago and is a Clinical Assistant Professor at the University of Chicago Pritzker School of Medicine where she is a leading expert in osteoporosis, psoriatic disease, and other immune-mediated diseases. Dr. Sandler is the Director of the Bone Health Center at Endeavor Health. She is also a board member of the National Psoriasis Foundation and in 2023 received the NPF Provider of the Year award in Rheumatology. Dr. Sandler is passionate about patient education and integrative team approaches when it comes to caring for patients with complex and multilevel diseases such as psoriatic arthritis, psoriasis and osteoporosis. /episode/index/show/psoundbytes/id/36760195

Ep 252 "Defining Minimal Disease Activity in Psoriatic Arthritis with rheumatologist Dr. Arthur Mandelin" 05/13/2025

Ep 252 "Defining Minimal Disease Activity in Psoriatic Arthritis with rheumatologist Dr. Arthur Mandelin" Not sure what Minimal Disease Activity or MDA is and how it relates to psoriatic arthritis and your joints? Listen as rheumatologist Dr. Arthur Mandelin explains what MDA means. Join hosts Jeff Brown and LB Herbert as they discuss minimal disease activity in psoriatic arthritis with nationally recognized rheumatologist Dr. Arthur Mandelin who identifies what it is, factors that influence achieving MDA, how long it takes to reach, and the impact on selection of treatments. Dr. Mandelin also addresses fatigue associated with inflammation, and what the future holds for minimal disease activity in psoriatic arthritis. Whether you have psoriasis or psoriatic arthritis, this episode offers information to help you understand management goals set by your doctor and the importance of attaining minimal disease activity. Timestamps: (00:00) Intro to Psound Bytes & guest welcome rheumatologist Dr. Arthur Mandelin (02:23) What is minimal disease activity (MDA) (04:32) MDA in comparison to ACR response criteria (07:36) Criteria for reaching MDA (09:20) Positive and negative factors of MDA (11:25) Importance of reaching MDA within a specific time frame (17:34) Length of time to reach MDA (18:48) Selection of treatment options and psoriatic arthritis domains (23:51) Inflammation and fatigue (26:59) A look at the future of minimal disease activity in psoriatic arthritis: Reaching ACR 90 (29:09) Advancements in psoriatic arthritis: Finding disease markers (33:40 ) If you have psoriasis, be aware of your risk for psoriatic arthritis 4 Key Takeaways: There are various ways to measure minimal disease activity in psoriatic arthritis to assess how the disease impacts quality of life. Attaining and keeping minimal disease activity low through use of different therapy options offers a chance for better bone and joint outcomes. Advancements in psoriatic arthritis include attaining ACR90 and the potential for identifying key markers that make treatment selection more targeted and individualized. Those who have psoriasis need to realize bone and joint pain, and swelling in the joints may be related to their psoriatic skin disease and seek appropriate help. Guest Bio: Dr. Arthur Mandelin is an Associate Professor of Medicine at Northwestern University Feinberg School of Medicine and the Department of Medicine Division of Rheumatology. Dr. Mandelin launched Northwestern University’s first training program in musculoskeletal ultrasonography for rheumatology fellows. He is an active participant in the REASON Group which is a multi-center research collaboration devoted to using ultrasound guidance to obtain minimally invasive synovial tissue biopsies. Dr. Mandelin is a past member of the National Psoriasis Foundation’s Medical Board where he served on consensus panels for the development of a variety of practice guidelines. Resources Mentioned: National Psoriasis Foundation: PEST Screener: PsA Action Month 2025: NSAIDS for Psoriatic Disease: AMP (Accelerated Medicines Partnership): Tags: psoriasis, skin, psoriatic arthritis, minimal disease activity, ACR20, ACR50, ACR70, tender joints, bone erosion, joint swelling, enthesitis, inflammation, pain, fatigue, axial disease, spinal involvement, treatment, NSAIDS, biologics, personalized medicine, dermatology, National Psoriasis Foundation, AMP, Psound Bytes podcast, Soundbites podcast /episode/index/show/psoundbytes/id/36545690

Ep. 251 "Managing Psoriasis in High Impact Sites is a Whole Different Ball Game" 05/06/2025

Ep. 250 "The Future of Psoriasis Care: Dr. Mona Shahriari Breaks Down New AAD Research & Personalized Treatments" 04/29/2025

Ep. 250 "The Future of Psoriasis Care: Dr. Mona Shahriari Breaks Down New AAD Research & Personalized Treatments" Explore groundbreaking updates in psoriasis and psoriatic arthritis research from the 2025 AAD Annual Meeting with dermatologist Dr. Mona Shahriari. Join host Archie Franklin and renowned dermatologist Dr. Mona Shahriari as they unpack the latest research and clinical insights into managing psoriatic disease. This episode dives into head-to-head therapeutic trials, fast-acting treatments for high-impact areas like scalp and nails, and a preview of emerging oral biologics and GLP-1 weight management therapies. Dr. Shahriari discusses real-world challenges in treating psoriasis and psoriatic arthritis, the rise of precision medicine, and how early intervention could alter disease progression. Whether you're a patient, clinician, or researcher, this conversation delivers critical updates on psoriasis care, including IL-17, IL-23, and TYK2 inhibitors, and their potential to revolutionize dermatology practice. Timestamps: (00:00) Intro to Psound Bytes & guest welcome Dr. Mona Shahriari (01:00) What the AAD 2025 conference revealed about psoriatic disease (02:10) Comparing IL-17 and IL-23 inhibitors: Trial results (06:00) Treating scalp, palmoplantar, and nail psoriasis (10:45) Genital psoriasis & the importance of psychosocial care (12:00) What’s new for Generalized Pustular Psoriasis (GPP) 14:35) The GUIDE Study: Early treatment & immune memory (18:00) Personalized medicine, oral IL-23s & emerging TYK2s (20:00) GLP-1 therapies for weight & inflammation control (23:00) Psoriasis, cardiovascular risk & comorbidities (24:00) Mental health, depression & the value of systemic treatment (26:00) A hopeful future: matching therapy to the patient 4 Key Takeaways: Head-to-head trials show IL-17s like ixekizumab outperform traditional TNF inhibitors and even some IL-23s in early, fast action. Precision therapy based on site (scalp, nails, genitalia) and comorbidities is now guiding real-world treatment selection. GLP-1 medications are emerging as effective adjuncts for psoriasis patients struggling with weight and inflammation. Early intervention—especially with IL-23 inhibitors—may reduce flares, limit disease progression, and improve mental health outcomes. Guest Bio: Dr. Mona Shahriari is an Associate Clinical Professor of Dermatology at Yale University and Co-Founder of Central Connecticut Dermatology. A leading voice in inflammatory skin conditions, she serves as Associate Director of Clinical Trials and Senior Editor for the Journal of Psoriasis and Psoriatic Arthritis, a National Psoriasis Foundation peer reviewed journal for health care providers. Dr. Shahriari is also a National Psoriasis Foundation Medical Board Member and frequent contributor to dermatological research and clinical education. Resources Mentioned: National Psoriasis Foundation: Subscribe to the Advance eNewsletter: AAD Annual Meeting Info: Learn More About Clinical Trials: Tags: psoriasis, psoriatic arthritis, IL-17, IL-23, biologics, personalized medicine, dermatology, GLP-1, weight management, immune memory, AAD 2025, TYK2 inhibitors, Dr. Mona Shahriari, National Psoriasis Foundation, Psound Bytes podcast, Soundbites podcast /episode/index/show/psoundbytes/id/36352050